公司资料
Intellia 股价、新闻与催化剂
- 股票代码:
- NTLA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
12.09 USD (+1.51%)
收盘价
最后更新: 2026年8月17日
1.83B USD
市值
股价为何变动
As of Aug 17, 2026, NTLA closed up 1.51% at $12.09. No new same-company headline was identified in the current news window.
公司概览
In Vivo CRISPR Gene Editing
Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies.
Hereditary Angioedema
Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed to reduce kallikrein production for hereditary angioedema. Positive Phase 3 HAELO results support a rolling BLA submission.
Transthyretin Amyloidosis
Nexiguran ziclumeran, or nex-z, targets the TTR gene to reduce production of transthyretin through a one-time in vivo edit.
ATTR Cardiomyopathy Program
The Phase 3 MAGNITUDE trial evaluates nex-z in transthyretin amyloidosis with cardiomyopathy, the larger of Intellia's two registrational ATTR indications.
Hereditary ATTR Polyneuropathy
MAGNITUDE-2 evaluates nex-z in hereditary transthyretin amyloidosis with polyneuropathy, extending the same editing candidate into a neurologic manifestation of the disease.
未来催化剂
- Completion of the rolling BLA submission for lonvo-z.
- Potential U.S. launch of lonvo-z in the first half of 2027, subject to approval.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。